Patents Assigned to Sanwa Kagaku Kenkyusho Co., Ltd.
-
Publication number: 20240091195Abstract: A medicine includes glycopyrronium salicylate or a solvate thereof, wherein the medicine is used for treating or preventing sialorrhea and the like. A therapeutic drug enables the treatment of sialorrhea by affixing and a novel salt of glycopyrronium is suitable for a transdermal absorptive preparation.Type: ApplicationFiled: February 4, 2022Publication date: March 21, 2024Applicant: SANWA KAGAKU KENKYUSHO CO., LTD.Inventors: Kazuhiro UECHI, Masao SAKAIRI, Sou SUGITANI, Nobutaka MORIMOTO, Kazuki TAKADA, Takehiko NAKAMURA
-
Publication number: 20230127437Abstract: The invention provides an antisense oligonucleotide capable of controlling ATN1 gene expression and treating dentatorubral-pallidoluysian atrophy. An inventive compound comprises a modified oligonucleotide consisting of 8 to 80 linked nucleosides and having a nucleobase sequence including at least 8 contiguous nucleobases that are complementary to a transcript of ATN1, or a pharmacologically acceptable salt thereof.Type: ApplicationFiled: January 29, 2021Publication date: April 27, 2023Applicants: SANWA KAGAKU KENKYUSHO CO., LTD., NISSAN CHEMICAL CORPORATIONInventors: Shinji HASHIMOTO, Izumi GOTO, Yusuke IRIYAMA
-
Patent number: 11619630Abstract: A test strip including: a first site that's a detection site, where a first antibody specifically binding to the substance to be measured is immobilized on a porous carrier; a second site that's a specimen liquid addition site, where a second labeled antibody binding to the substance to be measured and having a recognition site different from that of the first antibody is retained on a porous carrier to be movable; and a third site that is a specimen liquid or developer addition site, where colored microparticles bound with a substance binding to a label substance of the second antibody are retained on a porous carrier to be movable, wherein the second site is provided between the first and the third sites, and the specimen liquid or developer can move, due to capillarity, from the second site to the first and from the third to the first site.Type: GrantFiled: December 21, 2018Date of Patent: April 4, 2023Assignee: SANWA KAGAKU KENKYUSHO CO., LTD.Inventor: Osamu Takehiro
-
Publication number: 20200333336Abstract: A test strip including: a first site that's a detection site, where a first antibody specifically binding to the substance to be measured is immobilized on a porous carrier; a second site that's a specimen liquid addition site, where a second labeled antibody binding to the substance to be measured and having a recognition site different from that of the first antibody is retained on a porous carrier to be movable; and a third site that is a specimen liquid or developer addition site, where colored microparticles bound with a substance binding to a label substance of the second antibody are retained on a porous carrier to be movable, wherein the second site is provided between the first and the third sites, and the specimen liquid or developer can move, due to capillarity, from the second site to the first and from the third to the first site.Type: ApplicationFiled: December 21, 2018Publication date: October 22, 2020Applicant: SANWA KAGAKU KENKYUSHO CO., LTD.Inventor: Osamu TAKEHIRO
-
Publication number: 20200237720Abstract: An object he present invention is to provide a medicament for therapy of alcohol use disorder.Type: ApplicationFiled: February 28, 2018Publication date: July 30, 2020Applicants: SANWA KAGAKU KENKYUSHO CO., LTD., UBE INDUSTRIES, LTD.Inventors: Atsushi NAKAJIMA, Tokuyuki YAMASHITA
-
Patent number: 10392345Abstract: Disclosed herein are a crystal comprising a compound, which has ?-opioid receptor antagonistic action, few side effects, and high safety, and having high purity and excellent physical properties (stability, solubility, etc.), and a method for producing the crystal. The crystal is a crystal of a salt comprising: a compound represented by a formula (I) [wherein R2 is a hydrogen atom or a halogen atom, and R1 is a group selected from the group consisting of and an acid selected from the group consisting of hydrochloric acid, hydrobromic acid, and oxalic acid, or a hydrate thereof.Type: GrantFiled: May 19, 2016Date of Patent: August 27, 2019Assignees: SANWA KAGAKU KENKYUSHO CO., LTD., UBE INDUSTRIES, LTD.Inventors: Ryo Iwamura, Yasunori Tsuzaki, Hiroyuki Setoguchi, Hiroto Akaza, Yasuhito Yamamoto, Akira Takama, Yuka Kuno
-
Patent number: 9902087Abstract: Disclosed is a powdery material filling device with a redundant (i.e., excess or waste) powdery material recovering mechanism. The powdery material filling device may be used in a rotary compression molding machine. In certain aspects, the redundant powdery material recovering mechanism is capable of actively recovering and reusing a redundant (i.e., excess or waste) powdery material even upon production of multi-layer tablets.Type: GrantFiled: October 3, 2012Date of Patent: February 27, 2018Assignee: Sanwa Kagaku Kenkyusho Co., Ltd.Inventors: Yuichi Ozeki, Kentaro Izumi, Katsuhito Fujisaki, Kouichi Atagi
-
Patent number: 9663463Abstract: The object of the present invention is to provide a compound having an antagonistic action against ?-opioid receptors, which causes less side effects and thus is highly safe. A compound represented by the general formula (I), or a pharmacologically acceptable salt thereof: wherein R1 and R2 are the same or different, and each represents a hydrogen atom or a halogen atom, provided that R1 and R2 are not simultaneously halogen atoms, R3 represents a C1-C3 alkyl group or a vinyl group, and R4 represents the formula (II): wherein R5 represents a hydroxy group or a C1-C3 alkoxy group, and R6 and R7 are the same or different, and each represents a hydrogen atom or a halogen atom; or the formula (III): wherein Ring A represents a halogen atom(s)-substituted C5-C7 cycloalkyl group which is optionally substituted by a C1-C3 alkoxy group, or a halogen atom(s)-substituted 5- to 7-membered saturated heterocyclic group.Type: GrantFiled: November 19, 2014Date of Patent: May 30, 2017Assignees: SANWA KAGAKU KENKYUSHO CO., LTD., UBE INDUSTRIES, LTD.Inventors: Kaori Taniko, Toshiyuki Miyazawa, Tatsuroh Kaneko, Daisuke Kurumazuka, Satoko Harada, Toru Izuchi, Morio Okabe, Ryo Iwamura, Yasunori Tsuzaki, Hiroyuki Setoguchi, Yuuki Imura, Hiroto Akaza, Motohisa Shimizu, Tomio Kimura
-
Patent number: 9586905Abstract: A compound having a V2 receptor agonistic activity is provided. Providing a pharmaceutical composition which contains, as an active ingredient, a compound represented by general formula (I) described below: [R1 is formula described below: (A is a lower alkylene group which may be substituted with lower alkyl group; R6 is a hydrogen atom; R7 is a hydroxyl group, an aromatic heterocyclic group which may be substituted with lower alkyl group, carbamoyl group); R2 is a hydrogen atom or lower alkyl group; R3 is lower alkyl group which may be substituted with 1-3 fluorine atoms, or halogen atom; R4 is a five-membered aromatic monocyclic heterocyclic group, five-membered non-aromatic monocyclic heterocyclic group, (provided each heterocyclic groups contain at least one nitrogen atom and may be substituted with a lower alkyl group); and R5 is a lower alkyl group, halogen atom], or pharmacologically acceptable salt thereof.Type: GrantFiled: December 26, 2013Date of Patent: March 7, 2017Assignee: SANWA KAGAKU KENKYUSHO CO., LTD.Inventors: Katsunori Kitamoto, Nobuyoshi Kasugai, Hiroyo Kataoka, Yasushi Ohsawa, Yuka Kuno, Hiroki Fujieda, Keita Sakai, Hiroki Nagano, Naoki Takahashi, Toru Izuchi, Mitsuaki Takeuchi, Daisuke Kurumazuka, Toshiyuki Miyazawa, Satoko Harada, Izumi Gotoh, Yukiyasu Asano, Yurie Yamada, Morio Okabe
-
Publication number: 20160280645Abstract: The object of the present invention is to provide a compound having an antagonistic action against ?-opioid receptors, which causes less side effects and thus is highly safe. A compound represented by the general formula (I), or a pharmacologically acceptable salt thereof: wherein R1 and R2 are the same or different, and each represents a hydrogen atom or a halogen atom, provided that R1 and R2 are not simultaneously halogen atoms, R3 represents a C1-C3 alkyl group or a vinyl group, and R4 represents the formula (II): wherein R5 represents a hydroxy group or a C1-C3 alkoxy group, and R6 and R7 are the same or different, and each represents a hydrogen atom or a halogen atom; or the formula (III): wherein Ring A represents a halogen atom(s)-substituted C5-C7 cycloalkyl group which is optionally substituted by a C1-C3 alkoxy group, or a halogen atom(s)-substituted 5- to 7-membered saturated heterocyclic group.Type: ApplicationFiled: November 19, 2014Publication date: September 29, 2016Applicants: SANWA KAGAKU KENKYUSHO CO., LTD., UBE INDUSTRIES, LTD.Inventors: Kaori TANIKO, Toshiyuki MIYAZAWA, Tatsuroh KANEKO, Daisuke KURUMAZUKA, Satoko HARADA, Toru IZUCHI, Morio OKABE, Ryo IWAMURA, Yasunori TSUZAKI, Hiroyuki SETOGUCHI, Yuuki IMURA, Hiroto AKAZA, Motohisa SHIMIZU, Tomio KIMURA
-
Publication number: 20160136091Abstract: Disclosed is an orally disintegrating tablet including: (a) an active ingredient; (b) a starch with an amylose content of 20% by mass to 30% by mass and a degree of gelatinization of less than 10%; and (c) at least one inorganic excipient selected from the group consisting of magnesium silicate, calcium silicate, and synthetic hydrotalcite. The orally disintegrating tablet is a single-layer tablet or a dry-coated tablet having an inner core and an outer layer. The orally disintegrating tablet as a single-layer tablet or the outer layer of the orally disintegrating tablet as a dry-coated tablet has a crystalline cellulose content of 0% by mass to 5% by mass.Type: ApplicationFiled: July 17, 2014Publication date: May 19, 2016Applicant: SANWA KAGAKU KENKYUSHO CO., LTD.Inventors: Masahiro Kondo, Naoya Ochiai, Yuki Sakakura
-
Publication number: 20150239890Abstract: An object is to provide a crystal of anagliptin, which has a high purity and is excellent in stability, low in hygroscopicity, and has a characteristic of easily dissolving into water, and a method for producing the crystal. An anagliptin crystal showing a powder X-ray diffraction pattern substantially the same as in FIG. 1, which has peaks around at 9.8°, 17.4°, 18.6°, 25.3°, and 25.8° as diffraction angles represented by 2?. The crystal is obtained by reacting N-(2-amino-2-methylpropyl)-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide and (2S)—N-chloroacetyl-2-cyanopyrrolidine in an organic solvent, thereafter purifying the reaction solution by column chromatography to thus obtain an amorphia of anagliptin, and crystallizing the amorphia of anagliptin from 2-propanol.Type: ApplicationFiled: August 27, 2013Publication date: August 27, 2015Applicant: SANWA KAGAKU KENKYUSHO CO., LTD.Inventors: Masao Sakairi, Hideaki Inagaki, Mitsuru Oka, Takayo Murase
-
Publication number: 20140302009Abstract: A pharmaceutical for preventing or treating a disorder accompanied by ocular angiogenesis and/or increased ocular vascular permeability, composed of a combination of an anti-VEGF agent, and a pyrrolo[1,2-a]pyrazine derivative represented by a general formula (I): in the formula, R1 and R2 are simultaneously or individually each a hydrogen atom, a halogen atom, a trifluoromethyl group, a lower alkyl group, a lower alkoxy group or a nitro group, and R3 is a hydrogen atom, a halogen atom or a lower alkyl group, or a pharmacologically acceptable salt thereof.Type: ApplicationFiled: February 1, 2012Publication date: October 9, 2014Applicants: Sanwa Kagaku Kenkyusho Co., Ltd., Public University Corporation Nagoya City UniversityInventors: Yuichiro Ogura, Miho Nozaki, Atsushi Nakajima, Chihiro Hibi
-
Publication number: 20140234463Abstract: Disclosed is a powdery material filling device with a redundant (i.e., excess or waste) powdery material recovering mechanism. The powdery material filling device may be used in a rotary compression molding machine. In certain aspects, the redundant powdery material recovering mechanism is capable of actively recovering and reusing a redundant (i.e., excess or waste) powdery material even upon production of multi-layer tablets.Type: ApplicationFiled: October 3, 2012Publication date: August 21, 2014Applicants: Sanwa Kagaku Kenkyusho Co., Ltd., Kikusui Seisakusho Ltd.Inventors: Yuichi Ozeki, Kentaro Izumi, Katsuhito Fujisaki, Kouichi Atagi
-
Patent number: 8633199Abstract: The problem to be solved by the present invention is to provide a medicine which is excellent in the treatment of type 2 diabetes, diabetic complications or impaired glucose tolerance. The present invention provides a medicine characterized in that a compound represented by the following general formula (I), a salt thereof, or a solvate thereof, and at least one kind of other diabetic medicine: (wherein R1, R2, R3 and R4 are each a hydrogen atom, a trifluoromethyl group or a C1-3 alkyl group).Type: GrantFiled: May 12, 2009Date of Patent: January 21, 2014Assignee: Sanwa Kagaku Kenkyusho Co., Ltd.Inventors: Moritaka Goto, Satoko Yamashita, Keizo Nakaya, Tetsushi Tomoguri, Tsutomu Ishida, Masahiro Fuchigami
-
Publication number: 20130344524Abstract: In a method for detecting a glucagon-secretin family peptide in a sample, the sample is contacted with a cleaving agent capable of digesting the glucagon-secretin family peptide by cleaving a peptide bond of at least one aspartic acid within the glucagon-secretin family peptide and thereby generating a plurality of peptide fragments, at least one of the peptide fragments containing an N-terminal end of the glucagon-secretin family peptide. The peptide fragment that contains the N-terminal end of the glucagon-secretin family peptide is then detected using liquid chromatography and mass spectrometry. The amount of peptide fragment that contains the N-terminal end of the glucagon-secretin family peptide in the sample can then be quantitated using a calibration curve.Type: ApplicationFiled: March 7, 2012Publication date: December 26, 2013Applicant: SANWA KAGAKU KENKYUSHO CO., LTD.Inventors: Atsushi Miyachi, Yoshika Yasuda, Hiroko Hirooka
-
Patent number: 8536212Abstract: The present invention provides a protective agent for retinal nerve or optic nerve which exerts its effect through a different mechanism from that of conventional therapeutic agents and can be taken for long periods. The present invention is the protective agent for retinal nerve or optic nerve which comprises a compound with aldose reductase inhibiting activity such as the compound represented by the following general formula as an active ingredient. A preferable compound thereof is (2S,4S)-6-fluoro-2?,5?-dioxospiro[chroman-4,4?-imidazolidine]-2-carboxamide: wherein X represents a halogen atom or a hydrogen atom, R1 and R2 independently represent a hydrogen atom or an optionally substituted C1 to C6 alkyl group, or R1 and R2, together with a nitrogen atom bound thereto, or optionally another nitrogen atom or an oxygen atom, are combined to form a 5- to 6-membered heterocycle.Type: GrantFiled: January 30, 2008Date of Patent: September 17, 2013Assignee: Sanwa Kagaku Kenkyusho Co., Ltd.Inventors: Sookja Kim Chung, Stephen Chung, Chihiro Hibi
-
Publication number: 20130123460Abstract: The present invention aims at providing a peptide fragment capable of improving biostability of a bioactive substance while maintaining the activity of the bioactive substance, and a bioactive substance to which the peptide fragment is added. The present invention relates to a partial peptide of a GA module having 5 to 25 amino acids, including a partial sequence of a GA module (SEQ ID NO: 1) and the amino acid sequence Ile-Asp-Glu-Ile-Leu (SEQ ID NO: 2), and a bioactive complex in which the partial peptide of the GA module is bound to a bioactive substance. The bioactive substance includes GLP-1, GLP-2, GIP, VIP, somatostatin, amylin, ghrelin, derivatives thereof, and the like.Type: ApplicationFiled: April 28, 2011Publication date: May 16, 2013Applicant: SANWA KAGAKU KENKYUSHO CO., LTD.Inventors: Masayuki Okamoto, Ryuhji Okamoto, Tomohiro Shigemori, Takayo Murase, Atsushi Miyachi, Mitsuaki Takeuchi, Miyuki Tamura, Hiroshi Kinoshita
-
Publication number: 20130005698Abstract: A pharmaceutical for preventing or treating an inner ear disorder, comprising a spirohydantoin derivative represented by a general formula (I): in the formula, X represents a halogen atom or a hydrogen atom, and R1 and R2 simultaneously or individually represent a hydrogen atom or an optionally substituted C1-6 alkyl group, or a pharmacologically acceptable salt thereof as an active ingredient.Type: ApplicationFiled: April 25, 2011Publication date: January 3, 2013Applicants: University of Tsukuba, Sanwa Kagaku Kenkyusho Co., Ltd.Inventors: Akira Hara, Keiji Tabuchi, Chihiro Hibi
-
Publication number: 20120244102Abstract: The present invention is to provide an agent for treating Crohn's disease that is of unknown cause and for which no radical therapeutic drug is present. Provided is an agent for preventing or treating Crohn's disease, comprising an organic acid polymer represented by the following formula: [(O1/2)3Ge-A-CO2H]n, wherein n is 100-1,000, and A is a lower alkyl group. Preferably, A is a C1-C3 lower alkyl group and the degree of polymerization n is 200-900. The organic acid polymer according to the present invention is effective as an agent for treating Crohn's disease.Type: ApplicationFiled: January 26, 2011Publication date: September 27, 2012Applicant: SANWA KAGAKU KENKYUSHO CO., LTD.Inventors: Hiroyuki Hashimoto, Toshihiko Kumazawa, Motohiro Takeda, Takahito Jomori, Chihiro Hibi, Kuniharu Mizuno